ClinicalTrials.Veeva

Menu
A

Advanced Medical Research Institute | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Relamorelin
Vibegron
MT-2990
Triglycerides
Tolterodine
Aroxybutynin
AD109
ETX-018810
Atomoxetine
Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 21 total trials

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703...

Enrolling
Wound
Foot Ulcer
Drug: ENERGI-F703 GEL
Drug: ENERGI-F703 matched vehicle
Locations recently updated

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Ob...

Active, not recruiting
OSA
Drug: Placebo
Drug: AD109

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Allergan logo
Apnimed logo
U
A
E
E
Ionis Pharmaceuticals logo
Kowa logo
Mitsubishi Tanabe Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems